학술논문
Carcinogenicity Risk Assessment Supports the Chronic Safety of Dapagliflozin, an Inhibitor of Sodium–Glucose Co-Transporter 2, in the Treatment of Type 2 Diabetes Mellitus
Document Type
Article
Author
Source
In: Diabetes Therapy . (Diabetes Therapy, 1 June 2014, 5(1):73-96)
Subject
Language
English
ISSN
18696961
18696953
18696953